Mary Philip

color-enhanced cross section of tumor tissue
October 7, 2024

New Video: Study shows cancer vaccine blocks tumor progression at early lesion stage

Senior author Mary Philip, MD, PhD, associate director of the Vanderbilt Institute for Infection, Immunology and Inflammation, talks about her Journal for ImmunoTherapy of Cancer study.
The findings support further vaccine investigation to make long-term, progression-free survival a reality for more cancer patients.

By Tom Wilemon
T cells (orange) engage with cancer cells (blue). Halle Borowski, an artist and senior at the College of William and Mary, worked with Drs. Mary Philip and Jess Roetman to create this oil painting, inspired by their research, as part of the Vanderbilt Institute for Infection, Immunology, and Inflammation (VI4) Artist-in-Residence program (https://www.artlab-air.com/).
November 17, 2023

Tumor antigens key to improving cancer immunotherapy: study

Vanderbilt researchers are working to better design immune therapies that attack tumors without also attacking healthy normal tissue in patients.

By Bill Snyder
Mary Philip, MD, PhD, left, and Michael Rudloff, PhD, found that T cells become “exhausted” within hours of encountering a tumor, challenging existing ideas about how T cells become dysfunctional. (photo by Anthony Czelusniak)
August 3, 2023

Study finds hallmarks of T cell exhaustion within hours of tumor exposure

Vanderbilt researchers found that T cells become “exhausted” within hours of encountering a tumor, challenging existing ideas about how T cells become dysfunctional.

By Leigh MacMillan
June 18, 2019

Study identifies critical regulator of tumor-specific T cell differentiation

A study published June 17 in Nature offers clues as to why blocking inhibitory receptors on tumor-infiltrating T cells may not always work

By Tom Wilemon
December 13, 2018

Philip’s liver cancer research receives V Foundation support

Mary Philip, MD, PhD, has been named a 2019 V Scholar and will receive $200,000 from the V Foundation for Cancer Research.

By Tom Wilemon